Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara–Bavaria Nordic vaccine against mpox in children: a national outbreak response
Key Points
Key points are not available for this paper at this time.
Abstract
UK Health Security Agency.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara–Bavaria Nordic vaccine against mpox in children: a national outbreak response | Synapse